ContraFect Corp.(NASDAQ : CFRX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.16%||69.56||1.0%||$505.86m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.18%||635.16||2.7%||$472.48m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.31%||203.81||1.9%||$464.56m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-4.21%||4.10||0.7%||$286.61m|
|EXAS||EXACT Sciences Corp.||-4.94%||76.59||18.0%||$140.15m|
ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.